This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The worldwide pharmaceutical container packaging market is expected to rise in revenue from $104.12 billion in 2025 to approximately $174.45 billion by 2033, according to a study published by Towards Packaging. Specifically, the “high quality of biodegradable and recyclable packaging materials” are driving the market.
This rapid processing not only enhances throughput, but will also allow pharmaceuticalcompanies to respond more swiftly to market demands. DMC’s innovative design incorporates an ultrathin conductive layer, typically made of gold, which enables the application of electrical fields across ionic and affinity membrane adsorbers.
As we approach 2025, emerging trends are reshaping how the industry engages with patients and healthcare providers. From eco-friendly packaging to socially responsible campaigns, sustainability resonates with today’s consumers. Learn more about compliance tips at Pharma Marketing.
GlobalData Healthcare June 19, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The oligonucleotide market is well-positioned to drive the next wave of personalised treatment. billion from 2021 to 2025 year-to-date. Credit: Kateryna Kon via Shutterstock. ASOs accounted for more than half ($3.54
GlobalData Healthcare June 25, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The future Alzheimer’s disease treatment paradigm is anticipated to be combinatorial. The momentum in acquisition activity continued into 2025, with total deal value reaching $16.8 Credit: JLStock via Shutterstock.
Abigail Beaney June 25, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The EHDS has come into force but it has not yet been fully rolled out, with EU member states still in discussions over how the legislation will work. One of the two panels on EHDS at HLTH Europe 2025.
Robert Barrie June 6, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook US health secretary Robert F Kennedy Jr. In one of the fierier remarks from the roundtable, RFK Jr said: “At every level, doctors, other providers, our hospitals, the pharmaceuticalcompanies, the insurance companies, all make money by keeping us sick.
This article dives deep into how patient marketing has changed, whats driving this transformation, and what strategies are leading the way for 2025 and beyond. Additionally, integrating offline and online experiencessuch as QR codes on packaging leading to mobile resourcesenhances the continuity of care.
Pharmaceuticalcompanies are putting their trust in the immense potential this new generation of medicine has for treating individuals with rare genetic diseases, which currently affect an estimated 280 million patients worldwide. Products are stored and packaged in a dedicated suite by a dedicated team,” explains MacNeir.
The recent legislative reform proposals put forward by the European Commission (EC) have sparked significant discontent among pharmaceuticalcompanies. While a handful of incentives are offered by the reform package, they are overshadowed by the potential drawbacks for the innovative sector.
The patent protection for Nexplanon typically prevents other pharmaceuticalcompanies from creating a generic version until the patent expires. in 2027 and other countries in 2025, when a generic version may be approved. Most insurance companies offer health insurance plans that cover Nexplanon and other birth control methods.
link] A recent study published by My Green Lab 2 presented data from 74 biotechnology and pharmaceuticalcompanies tracking the change in scope 1, 2, and 3 carbon intensity (measured in tons of CO2 emitted vs. the company’s revenue in USD) since 2015. For pharmaceuticalcompanies, purchased goods (e.g.,
Uruguay’s new left-wing coalition government took office in March 2025, under President Yamandu Orsi. The government therefore is advocating for the creation of the new drug regulatory agency to expedite economic growth, streamline drug approvals and attract international pharmaceuticalcompanies to invest in the country.
Supporting sterile barrier packaging and supply chain resilience The Madison plant reinforces the TekniPlex Healthcare’s goal of assisting pharma and medical companies, which indirectly includes its downstream partners as well. June 12, 2025. Accessed June 18, 2025. Pharmaceutical Commerce. May 6, 2025.
Shifts in sterile manufacturing include isolator tech adoption and packaging tailored to personalized medicine, at-home use, and chronic disease treatments. Sterile capsules for injection. . At that time, Mahler said revisions to regulatory guidance were having an impact on fill/finish facilities.
Compounded semaglutide is made by special compounding pharmacies rather than pharmaceuticalcompanies. For those licensed by the state, the deadline is April 22, 2025. For those licensed by the FDA, the deadline is May 22, 2025. A monthly supply of semaglutide ranges from about $129$1,850 without insurance.
According to the GlobalData report Contract Injectable Packaging Trends in the Bio/Pharma Industry , more than half (55%) of FDA drug approvals in 2021 were accounted for by injectables. During the Covid-19 pandemic, large-scale vaccine production placed unprecedented demand on the parenteral packaging industry.
To further expedite the introduction of the biosimilar globally, EirGenix has been in talks with global pharmaceuticalcompanies about licensing the marketing rights to EG1206A 5. The P-III trial of EG1206A is expected to be initiated shortly, estimated that the evaluation of the primary EPs will be completed within 2yrs.
Robert Barrie June 25, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook RFK Jr has embarked on a mission to reset vaccine regulation and evidence generation in the US. In May 2025, he said that all new vaccines would need to be developed without using mRNA technology. Credit: Novikov Aleksey via Shutterstock.
Miranda McLaren June 30, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook When Donald Trump was elected the 47 th president of the United States of America, the outlook for pharmaceuticals was unclear, with 55% of North American industry professionals expecting negative repercussions when surveyed by GlobalData later that month.
Robert Barrie and Ross Law June 10, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The removal ACIP members marks the most significant upheaval to the current vaccine landscape under Trump’s administration. lev radin via Shutterstock. Give your business an edge with our leading industry insights.
Robert Barrie June 27, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook The list price for a month’s supply of 2.4mg Wegovy – the drug’s highest does – is $1,350 in the US, whereas the same dose in the UK costs £175.80 each month. “I Mochi Health is even the subject of a lawsuit initiated by Eli Lilly.
Leyla Hasanzadeh June 18, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Tech transfer for manufacturing purposes in India will be difficult if Trump imposes import duties on pharmaceuticals. The next few weeks of June and July 2025 will be pivotal for their trade relationship as negotiations enter advanced stages.
Robert Barrie June 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Drugmakers have poured billions of dollars into pharma manufacturing facilities across the US as they adapt to macroeconomic pressures. Novartis, Eli Lilly, and Genentech have also made US investment announcements in the wake of Trump’s reforms.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content